Agile Therapeutics Secures $7.5 Million to Boost Development Efforts

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, is excited to announce the pricing of their public offering showcasing 1,896,286 shares of their common stock (or pre-funded warrants) and accompanying common stock warrants.

At a public offering price of $3.9551 per share (or pre-funded warrant) and accompanying warrants, this offering provides an opportunity to purchase one share of common stock, coupled with a Series C-1 warrant that is exercisable immediately and expires five years from the date of issuance, and a Series C-2 warrant that is exercisable and expires eighteen months from the date of issuance. Total gross proceeds are expected to be approximately $7.5 million before deducting the placement agent’s fees and other offering expenses.

H.C. Wainwright & Co. is delighted to be playing a pivotal role in the offering with its exclusive placement agent services. We are committed to helping our clients make smart, informed investments.

The company is pleased to announce the upcoming closing of its offering on or around May 25, 2023, subject to the satisfaction of customary closing conditions. Proceeds from this offering will be used for working capital, business development initiatives, and other general corporate purposes. The securities being offered were registered with the SEC on Form S-1 (File No. 333-271249) and declared effective on May 22, 2023. To learn more, please review the prospectus forming part of the effective registration statement relating to the offering.

As part of this offering, the Company has agreed to amend certain existing warrants that had been issued between October 2021 and July 2022. These warrants, initially exercisable at $45.00 to $1,700.00 per share, will now allow the holders to purchase up to an aggregate of 229,669 shares of the Company’s common stock at just $3.69 per share, expiring five years from the closing of the offering.

Don’t miss out on your chance to own a piece of history! We are offering an incredible opportunity to invest in these securities – an offer not to be missed! There are no restrictions on the sale of these securities in any state or jurisdiction, so don’t wait any longer – seize this exclusive offer and make your dreams a reality today!


Agile Therapeutics is a groundbreaking women’s healthcare company with the mission of catering to the unmet needs of today’s women. We are focusing on creating innovative contraceptive options that allow women the freedom to forget about taking a daily pill.

Our first product, Twirla®, (levonorgestrel and ethinyl estradiol), is a revolutionary transdermal system, and is only the beginning of our journey in finding new and exciting methods of contraception. Our proprietary transdermal patch technology, called Skinfusion®, is designed to allow the drug to be effectively delivered through the skin. Take control of your fertility with Agile Therapeutics today!


This press release contains forward-looking statements regarding the offering and our use of the proceeds from the offering. Such statements are based on our current beliefs and assumptions and involve knowledge of risks, uncertainties, and other factors that could potentially affect the success of these initiatives. We are aware that any of these statements may possibly be wrong or affected by inaccurate assumptions, risks, and uncertainties that can come from various important factors. These factors include, but are not limited to, changes in the market, closing conditions, use of proceeds, and other associated risks.

For a better understanding of the risks and potential uncertainties, please refer to our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. We encourage you to be aware of these risks as you make any decisions related to our offerings. We are committed to updating any forward-looking statements as required by law and depending on the changes in circumstances and risks.

Leave a Comment